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Abstract
We compared gentamicin pharmacokinetics among neonates born small‐for‐gestational age (SGA) and appropriate for gestational age (AGA). We
further compared gentamicin pharmacokinetics in subgroups of AGA and SGA neonates born preterm and term and treated within and after the initial
week of age. Steady state peak and trough serum gentamicin concentrations were used to calculate clearance (Cl), elimination constant (Kel), volume of
distribution (Vd), and half‐life (t1/2) in infants (n¼ 236) who received48 hours therapy. Statistical analyses (SPSS 17.0) included chi‐square and the non‐
parametric Mann–Whitney U‐test. SGA infants treated early (7days) (n¼ 29) and at postmenstrual ages 32 weeks (n¼ 23) had significantly lower
median Kel (0.069/h vs. 0.081/h and 0.067/h vs. 0.075/h) and clearance (0.58mL/kg/min vs. 0.68mL/kg/min and 0.46mL/kg/min vs. 0.65mL/kg/min),
compared to those born AGA. There were no significant differences in pharmacokinetic profiles with later therapy or at more mature ages. The
prolonged half‐life of gentamicin may need to be considered in dosing regimens for preterm SGA infants in the initial week of life.
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Gentamicin is a commonly used aminoglycoside in
neonates, both in empiric and treatment regimens for
bacterial pathogens isolated in the Neonatal Intensive Care
Unit (NICU). Gentamicin is eliminated unchanged in the
urine, almost exclusively by glomerular ﬁltration and has
low (<30%) protein binding.1–3 Gentamicin dosing
regimens have included traditional lower doses at more
frequent intervals or extended‐interval higher dose
regimens.1–5 The weight‐based gentamicin extended‐
interval dosing regimens aim to achieve adequate peak
concentrations to ensure pathogen killing while avoiding
elevated trough concentrations, which may be associated
with toxicity.4,6 In preterm infants, weight‐based dosing
regimens are adjusted further for developmental stages or
postmenstrual age to account for maturational changes in
renal excretion.7,8
The effect of small‐for‐gestational age (SGA) status in
neonates on gentamicin pharmacokinetic parameters of
clearance and elimination has not been previously
examined. SGA status, which may be a result of
intrauterine growth restriction (IUGR), may be associated
with a decrease in nephron number and renal organ mass,
altered tubular function, and impaired glomerular ﬁltra-
tion.8–11 In limited studies with other medications, the
impact of intrauterine growth restriction appears to vary
with postnatal and postmenstrual age.7,12–13 This may be,
in part, due to lower creatinine clearance in the initial 5–10
days of life, speciﬁcally in those born preterm.14 Further,
gestational age, postnatal age, other clinical factors such as
hypoxemia have all been shown to affect drug clearance in
neonates, with postmenstrual age having the greatest
effect on drug clearance.15–17 Therefore, the speciﬁc aims
of this study were to compare gentamicin pharmacokinetic
parameters in infants born SGA and those born AGA; and,
in subgroups of AGA and SGA infants who were
administered the drug early (1 week of age) and late
(>1 week) and, ﬁnally, in subgroups of AGA and SGA
infants whose postmenstrual age at the time of gentamicin
administration was 32 weeks and >32 weeks.
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Material and Methods
This was a retrospective chart review of consecutive
infants who received gentamicin for 48 hours in the
NICU at Hutzel Women’s Hospital over a 7‐year period
between 2004 and 2010 and had at least one gentamicin
serum concentration measured. The 7‐year study period
was selected because of availability of electronic
searchable pharmacy database; a simpliﬁed extended‐
interval dosing nomogram was initiated early in the study
period and was used for most of the infants. Infants were
identiﬁed from the electronic database using “gentamicin”
and “antibiotics” as search words. The patient list was
validated using the pharmacy database. The dosing
regimen for early (<7days of age) onset sepsis was
3mg/kg IV q 36 hours for infants <1,200 g, 3mg/kg IV q
24 hours for infants 1,200–2,000 g and 3.5mg/kg IV q
24 hours for infants >2 kg at birth. For gentamicin use
beyond 7 days, doses of 3–4mg/kg q 24 hours were
administered for infants<1,200 g, 4mg/kg q 24 hours for
infants who weighed 1,200–2,000 g and 4–5mg/kg q
24 hours for those who weighed>2 kg. Gentamicin doses
were infused over a 0.5‐hour‐period. Permission to access
the medical records and electronic databases with waiver
of parental consent were obtained from the Wayne State
University Investigational Review Board and Detroit
Medical Center Research Review.
In our institution, gentamicin concentrations were
measured in all infants who were administered the drug
for 48 hours. Peak (Cpmax) and trough (Cpmin)
concentrations of gentamicin were timed with Cpmin
being obtained 0.5 hour prior to a dose and Cpmax
0.5 hour following the end of infusion of the dose to
allow for distribution of the drug. Clinical pharmacists
entered orders for gentamicin levels according to a
system protocol and speciﬁed the exact time and date for
peak and trough collection to ensure that samples were
obtained between the third and fourth doses, assumed to
be steady state concentrations. Variability in sampling
time was minimal. The initial doses for each patient
were based on the simpliﬁed dosing nomogram. Exact
dosing regimens and collection times were noted for the
analysis. Table 1 is a description of the distribution of
the frequency sampling by dosing regimen. Estimated
postdistribution peak concentrations were calculated
from two drug concentrations (peak and trough) using a
single compartment model and ﬁrst order Sawchuk‐
Zaske pharmacokinetic equations by the pharmacist.18
The gentamicin dose, interval, peak (Cpmax) and
trough (Cpmin) concentrations for each patient at
assumed steady state were used to calculate clearance
of the drug (Cl), volume of distribution (Vd) and the
elimination rate constant (kel1). Therapeutic range of
Cpmax and Cpmin concentrations were deﬁned as
6–10mcg/mL and <1mcg/mL, respectively.19 Dose
adjustments post levels were required for gentamicin
peak levels >10 mcg/mL or gentamicin trough levels
>1.2 mcg/mL.
Gentamicin serum samples were analyzed using
turbidometric inhibition immunoassay technique (Sie-
mens Healthcare Diagnostics). Medical and pharmacy
records, and laboratory results were reviewed to obtain
neonatal demographic and clinical data. Gestational age
was recorded from the medical records from the history
and physical and is typically the best obstetric estimate,
if available, or a postnatal estimate using Ballard scoring,
if unavailable. Infants were classiﬁed as AGA (10th–
90th gender‐speciﬁc centile) or SGA (<10th gender‐
speciﬁc centile) using the Olsen growth curves.20
Postmenstrual age was calculated, as is the convention,
as the sum of gestational age (weeks) at birth and the
postnatal age (weeks). Assumed steady state gentamicin
Cpmax and Cpmin (mcg/ml) were used to calculate half‐
life (t1/2) in hours, elimination rate constant (kel
1) in
hour1, volume of distribution (Vd) in L/kg and
clearance (ml/kg/min). Statistical analysis was per-
formed using SPSS version 17 (SPSS, Inc., Chicago,
IL, USA). Descriptive statistics included number (%),
mean (SD) and median (range) values as appropriate.
The Shapiro–Wilk test of normality of data revealed a
non‐normal distribution of pharmacokinetic parameters;
therefore all further comparisons of continuous data
were performed using the non‐parametric Mann–Whit-
ney U‐test. Comparisons of categorical variables
between groups were performed using chi‐square test.
Signiﬁcance was taken as a P‐value <.05.
Results
A total of 236 infants were treated with gentamicin during
the study period and underwent therapeutic drug
monitoring (TDM). All gentamicin concentrations were
obtained after the 3rd dose, which were assumed to be
steady state concentrations. A second set of peak and
trough Cpmax and Cpmin measurements were obtained in
23 (9.7%) infants and 1 infant had a 3rd gentamicin peak
and trough concentration obtained.
Table 1. Distribution of Frequency of Sampling (n¼ 236)
Dose (mg/kg/dose) Frequency
2.5 q12 34
2.5 q24 10
3 q24 61
3 q36 32
3.5 q24 49
3.5 q36 30
4 q24 19
4.5 q24 1
Total 236
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Clinical Profile
The mean (SD) gestational age at birth was 30.8 (5.4)
weeks and mean (SD) birth weight was 1,641 (1,012) g.
The vast majority [194 (82%)] of our cohort was born
preterm (<37 weeks gestational age). Males comprised
54.7% of the cohort. Forty‐eight (20%) infants in the study
cohort were SGA at birth. The mean (SD) postnatal age at
which gentamicin TDMwas performed was 13 (19) days. At
the time of TDM, serum creatinine levels were 0.5mg/dL
or less in 75 (32%) infants, between 0.6 and 1mg/dL in
133 (56%) infants, between 1.1 and 1.5 in 21 (9%) and
above 1.5mg/dL in 2 (0.8%) infants; measurements were
unavailable in 5 (2.2%) infants. Mean (SD) serum
creatinine was 0.7 (0.3)mg/dL. An adjustment in gentami-
cin dosingwas required in 54 (23%) infants, based on initial
gentamicin serum concentrations. Bacteria were isolated
from the blood in 21 (8.9%) infants; they comprised gram
negative bacilli, (12) gram positive cocci (8) and gram
positive bacilli. (1) Respiratory endotracheal cultures were
positive in 41 (17.4%) infants for gramnegative bacilli, (28)
gram positive cocci (5) and multiple organisms. (8) Spinal
ﬂuid cultures were performed in 89 (38%) infants and were
negative in all cases. Concomitant vancomycin was
administered in 9 and indomethacin in 2 infants.
Effect of SGA Status on Gentamicin TDM
When infants born SGA (n¼ 48) were compared with
those born AGA (n¼ 188), the median (IQR) birth
weights [752.5 (546–1,746) g vs. 1,400 (880–2,635) g,
P¼ .0001] and weight at the time of TDM [1,265 (610–
1,865) g vs. 1572.5 (930–2,599) g, P¼ .005] were
signiﬁcantly different between groups. The median
(IQR) durations of therapy in SGA and AGA infants
were identical at 77–10 days. All TDM parameters were
comparable between groups.
Effect of SGA Status on TDM Parameters With Early
and Late Gentamicin Therapy
We then separately analyzed the effects of SGA status on
gentamicin TDM performed within the initial week (7
days) of life. When infants born SGA (n¼ 29) were
compared with those born AGA (n¼ 135), the median
birth weights and weights at the time of TDM were
signiﬁcantly different (Table 2). In addition, clearance was
signiﬁcantly lower in those born SGA, whereas T1/2 was
signiﬁcantly longer (P< .05).
Among infants who underwent gentamicin TDM after
7 days of age, there were signiﬁcant differences between
those born SGA (n¼ 19) and those born AGA (n¼ 53) in
median birth weights, age at TDM, Cpmin, and serum
creatinine (Table 3). At the time of TDM, 39 infants were
below the 10th centile for gender‐speciﬁc postmenstrual
age. Of the 19 infants who were SGA at birth, 18 remained
below the 10th centile for gender‐speciﬁc postmenstrual
age. Themedian (IQR) durations of therapy in both groups
were 10 (7–14) days.
Effect of SGA Status on TDM Parameters in Preterm
Infants With Postmenstrual Age 32 Weeks and Those
>32 Weeks
Figures 1 and 2 depict mean (SE) clearance and half‐lives
by postmenstrual age in subgroups of infants born AGA
and SGA. Among infants with postmenstrual age 32
weeks, those born SGA (n¼ 23) had signiﬁcantly lower
median clearance and prolonged t1/2, compared to those
born AGA (n¼ 111) (Table 4). Among infants with
postmenstrual age>32 weeks, SGA and AGA infants had
comparable pharmacokinetic parameters. The median
gestational ages, birth weights, age at TDM and weight
at TDM remained signiﬁcantly different between SGA
and AGA subgroups administered gentamicin at >32
weeks postmenstrual age.
Discussion
Among neonates administered a weight‐based extended‐
interval dosing of gentamicin in the initial week of life and
at postmenstrual ages at or below 32 weeks, gentamicin
clearance was decreased and half‐life was prolonged in
Table 2. Comparison of Median (IQR) Baseline and TDM Parameters Between Groups of SGA (n¼ 29) and AGA (n¼ 135) Infants Who Underwent
Gentamicin TDM at 7 Days of Life
Median (IQR) SGA (n¼ 29) AGA (n¼ 135) P‐value by Mann–Whitney U‐test
Gestational age (weeks) 30 (27–38) 32 (27–38) .694
Birth weight (g) 770 (545–2,312) 1,850 (1,030–2,980) .0001
Gentamicin dose (mg/kg/dose) 3.1 (3.0–3.4) 3.3 (2.9–3.5) .082
Age at TDM (days) 4 (3.5–4) 4 (3–5) .317
Weight at TDM (g) 860 (535–2,300) 1,780 (920–2,940) .001
Kel (hour1) 0.069 (0.050–0.081) 0.081 (0.064–0.106) .017
T1/2 (hours) 10 (8.5–14.1) 8.6 (6.9–10.8) .008
Clearance (mL/kg/min) 0.58 (0.41–0.84) 0.68 (0.57–0.90) .036
Vd (L/kg) 0.5 (0.41–0.67) 0.5 (0.42–0.62) .969
Cpmax (mcg/mL) 7.7 (5.5–8.5) 7.6 (6.2–8.6) .645
Cpmin (mcg/mL) 1.2 (1.1–1.6) 1.1 (0.8–1.6) .278
Serum creatinine (mg/dL) 0.8 (0.5–1.1) 0.8 (0.6–0.9) .524
Lulic‐Botica et al 41
those born SGA, compared to their AGA counterparts.
Beyond aweek of age and beyond 32weeks postmenstrual
ages, these differences were no longer apparent. Infants
born SGA and administered gentamicin after 1 week of
age did have signiﬁcantly lower trough concentrations.
This was probably related to older age and lower serum
creatinine in this group, compared to those born AGA.
Clinical pharmacokinetics of aminoglycosides in neo-
nates vary substantially compared to adults due to ongoing
developmental changes in drug absorption, distribution,
metabolism, and excretion.1 The higher total body water
and fraction of extracellular water, compared to adults,
resulted in higher volume of drug distribution in neonates,
with reported values of 0.5–0.7L/kg in premature infants,
0.2–0.5L/kg in children and 0.2–0.3 L/kg in adults
respectively.1,22 The half‐life of gentamicin rapidly
changes with postnatal renal maturation, with reported
values of 3–11.5 hours in the term neonate<1week of age,
3–5 hours in the older infant and 1.5–3 hours in the adult,
respectively. In a recent review of pharmacokinetics in
neonates, Paciﬁci noted variability, with half‐lives ranging
from 4.9 to 14.6 hours, clearance from 0.53 to 1.72mL/kg/
min and volume of distribution ranging from 0.45 to
0.75 L/kg.1 The author emphasized the need for individu-
alized therapy, especially for premature infants for this
reason.1 Due to the accelerated maturation of renal tubules,
there is an increased clearance of aminoglycosides with
increasing gestational ages.23–25 Ariano et al. used
Table 3. Comparison of Median (IQR) Baseline and TDM Parameters Between Groups of SGA (n¼ 19) and AGA (n¼ 53) Infants Who Underwent
Gentamicin TDM at >7 Days of Life
Median (IQR) or n (%) SGA (n¼ 19) AGA (n¼ 53) P‐value
Gestational age (weeks) 28 (25–31) 27 (26–30) 0.847
Birth weight (g) 750 (545–879) 1,030 (750–1,380) .004
Gentamicin dose (mg/kg/dose) 3.1 (2.8–3.3) 3.1 (2.9–3.5) .599
Age at TDM (days) 44 (21–75) 22 (13–42) .021
Weight at TDM (g) 1,420 (1,020–1,745) 1,280 (980–1,703) .848
<10th centile PMA at TDM 18 (95%) 21 (40%) .001
Kel (hour1) 0.107 (0.086–0.124) 0.095 (0.081–0.111) .195
T1/2 (hours) 6.5 (5.6–8.1) 7.3 (6.25–8.6) .138
Clearance (mL/kg/min) 0.90 (0.77–1.05) 0.80 (0.67–0.95) .197
Vd (L/kg) 0.5 (0.4–0.6) 0.5 (0.4–0.6) .919
Cpmax (mcg/mL) 7 (5.5–8.4) 6.9 (5.4–8.05) .964
Cpmin (mcg/mL) 0.5 (0.3–0.6) 0.7 (0.5–0.9) .013
Serum creatinine (mg/dL) 0.3 (0.3–0.5) 0.5 (0.35–0.60) .04
P‐value by Mann–Whitney U‐test.
Figure 1. Box plot showing median (IQR) clearance (mL/kg/min) by postmenstrual age of infants born AGA and SGA.
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Bayesian analysis and a dosing nomogram in 58 neonates
and found that those born at 34 weeks gestation had a
weight‐normalized apparent volume of gentamicin distri-
bution 1.6 times larger than infants born after 34 weeks’
gestation while weight‐normalized clearance was 22%
lower. Only 33% of predicted peak serum gentamicin
concentrations were >6mg/L for neonates born at or
below 34 weeks’ gestation, whereas 90% were therapeutic
in neonates born at older gestations.26 Young and
Mangum27 have previously suggested higher gentamicin
doses during the ﬁrst week of life for infants born at lower
gestational ages. In contrast, others have reported that more
than gestational age or postnatal age, creatinine clearance,
which is related to gestational age, plays an important role
in the elimination of gentamicin in premature newborns.2
Our data are broadly consistent with previous reported
ranges for pharmacokinetic variables.
The effect of varying weights on gentamicin pharma-
cokinetics in adults has been evaluated in a few studies.
Pai et al.28 examined gentamicin pharmacokinetics in
more than 1,500 adults across the extremes of weight
using a variety of bodymass descriptors and found that the
lean body weight, rather than true body weight or ideal
body weight, normalized the volume of distribution across
all weight categories and was the best parameter for initial
dosing. In another study in adults, dosing weight
Figure 2. Box plot showing median (IQR) half‐life (hours) by postmenstrual age of infants born AGA and SGA.
Table 4. Comparison of Median (IQR) Baseline and TDM Parameters Between Groups of SGA (n¼ 23) and AGA (n¼ 111) Infants Who Underwent
Gentamicin TDM at 32 Weeks Postmenstrual Age
Median (IQR) SGA (n¼ 23) AGA (n¼ 111) P‐value
Gestational age (weeks) 27 (25–28) 27 (25–29) .508
Birth weight (g) 630 (470–750) 1,030 (740–1,360) .0001
Gentamicin dose (mg/kg/dose) 3.1 (2.9–3.3) 3.2 (2.9–3.5) .176
Age at TDM (days) 4 (4–8) 5 (4–13) .286
Weight at TDM (g) 600 (480–860) 1,050 (750–1,360) .0001
Postmenstrual age at TDM (weeks) 28 (25–30) 29 (26–31) .40
Kel (hour1) 0.067 (0.046–0.075) 0.075 (0.060–0.095) .007
T1/2 (hours) 11.2 (9.3–15.1) 9.6 (7.6–11.7) .006
Clearance (mL/kg/min) 0.46 (0.39–0.69) 0.65 (0.53–0.83) .002
Vd (L/kg) 0.5 (0.4–0.7) 0.5 (0.4–0.7) .825
Cpmax (mcg/mL) 8 (5.6–8.5) 7 (5.8–8.2) .592
Cpmin (mcg/mL) 1.2 (0.65–1.60) 0.9 (0.7–1.4) .318
Serum creatinine (mg/dL) 0.9 (0.5–1.1) 0.8 (0.6–1.0) .243
P‐value by Mann–Whitney U‐test.
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correction factors to give equivalent predicted peak
aminoglycoside concentrations with a 2mg/kg loading
dose were 1.13 times the total body weight for
underweight patients.21 The effect of SGA status on
drug pharmacokinetics in neonates has been examined in a
few previous studies. Schreuder et al.16 evaluated
amikacin clearance in 161 neonates who received
amikacin within 24 hours of birth. Birth weight z‐score
and gestational age were correlated with amikacin
clearance with partial correlation coefﬁcients of 0.159
and 0.396, respectively, after correction of other factors.
Amikacin clearance was signiﬁcantly lower in the lowest
quartile birth weight z‐score group of infants, compared to
the highest quartile z‐score (0.56mL/kg/min vs. 0.64mL/
kg/min). Frattarelli et al.12 studied the impact of SGA
status on vancomycin pharmacokinetics among 143
infants. Overall Vd, clearance and half‐life did not differ
between SGA and AGA infants; speciﬁc subgroups of
SGA infants: 3–4 weeks old (0.031 L/h vs. 0.088 L/h) and
with a postconceptional age of 27–29weeks (0.021 L/h vs.
0.066 L/h) had decreased clearance, compared to infants
born AGA. Allegaert et al.15 investigated the same
research question using population pharmacokinetic
studies on preterm neonates within the ﬁrst month of
life for vancomycin (648 drug concentration measures)
and amikacin (282 measures). Neonates born small‐for‐
gestational age (SGA) were found to have a 16.2%
(coefﬁcient of variation, 12.2%) reduction in drug
clearance from birth up to a postnatal age of 4 weeks.
Weight explained 47.3% of drug clearance; postmenstrual
age, 25.2%; co‐administration of a nonselective cyclo‐
oxygenase inhibitor, 3.5%; renal function, 7.6%; and
SGA, 1.7%. The results of the current and these previous
studies are all remarkably consistent; clearance of drugs
excreted by kidney is decreased in SGA infants, especially
in the early postnatal and postmenstrual weeks of life. In
previous studies, postmenstrual age has been shown to be
a predictor or major determinant of aminoglycoside
clearance, “presumably because it predicts the time course
of development of glomerular ﬁltration.”15,29
The mechanism of impaired clearance in SGA infants is
probably related to low glomerular ﬁltration rate. Intrauter-
ine growth restriction is associated with a reduction in the
normalized weight of the kidney, the number of nephrons,
the glomerular ﬁltration rate and tubular function.30 A
compensatory hypertrophy with hyperﬁltration is also
thought to occur in theﬁrst months of life.8,9,11 Renal blood
ﬂow normalized to weight, urine output and fractional
excretion of sodium have been shown to be comparable in
SGA and AGA animal models, suggesting functional
compensation. It is plausible, therefore, that the early
reduction in clearance normalizes over time.
Our study has some limitations. Our cohort varied in
their gestational ages, postnatal and postmenstrual ages at
gentamicin administration and may have had comorbid-
ities such as sepsis, and patent ductus arteriosus that may
have affected gentamicin clearance. Infants were classiﬁed
as SGA based on birth weight and may or may not have
had IUGR. Our classiﬁcations of early and late therapy
and the cut‐off for postmenstrual ages, although based on
previous data and our dosing regimen, were arbitrary. The
strengths of our study include the fairly large sample size,
our inclusion of all neonates who had gentamicin
concentrations measured, our inclusion of several ex-
tremely preterm (43% 28 weeks) infants, a consistent
dosing regimen and TDM protocol and the SGA
categorization by recent North American Olsen growth
curves.
Several studies have shown that dosing of drugs in
neonates, especially in preterm neonates, when extrapo-
lated from adult or pediatric studies, often result in
variable serum concentrations. In addition, intra and extra‐
uterine growth restriction, although frequent in preterm
neonates, have not traditionally been accounted for in
neonatal dosing regimens. The current study provides
novel insights into the effect of SGA status on gentamicin
pharmacokinetics. Our results suggest that, while volume
of distribution is unaltered, the prolonged half‐life in SGA
infants needs to be considered in dosing regimens,
especially in the initial week of life and at early
postmenstrual ages. We speculate that these alterations
may be particularly important in patients with impaired
renal function, high‐dose or prolonged therapy and with
concomitant nephrotoxic medications. Regimens taking
the SGA status into consideration may achieve therapeutic
drug concentrations more rapidly, reduce the need for dose
adjustments and most importantly, may reduce nephro-
toxicity, which is related to the renal cortical aminoglyco-
side concentration. Further pharmacokinetic modeling is
required to elucidate the extent of the effect of SGA on
gentamicin pharmacokinetics.
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